Andrea P. Garzón-Partida

Ms. Andrea P. Garzón-Partida

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2025 in JMIR Research Protocols
Verified
Journal Article
Open access
AGAndrea P. Garzón-Partida
Andrea P. Garzón-Partida
KMKimberly Magaña-Plascencia
Kimberly Magaña-Plascencia
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
JGJoaquin Garcia-Estrada
Joaquin Garcia-Estrada
SLSonia Luquin
Sonia Luquin
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
Background: Substance use disorder (SUD) involves excessive substance consumption and persistent reward-seeking behaviors, leading to serious physical, cognitive, and social consequences. This disorder is a global health crisis tied to increased mortality, unemployment, and reduced quality of life. Altered brain connectivity, circadian rhythms, and dopaminergic pathways contribute to sleep disorders, anxiety, and stress, which worsen SUD severity and relapse. Factors like trauma and socioeconomic disadvantages heighten risk. Digital health technologies, including wearables and machine learning, show promise for diagnosis, monitoring, and intervention, from relapse prediction to early detection of comorbidities. With high relapse rates and younger patient cases, these innovations could enhance the treatment outcomes of SUD. Objective: The objective of this study is to develop and validate a predictive model with machine learning for the duration of therapy and the rehabilitation or relapse in patients with SUD, using digital physiological measurements, psychological profiles, automatic facial emotion recognition, and the emotional state during craving. Methods: The study will be conducted with adult male patients with SUD at a rehabilitation center and control volunteers. Participants will undergo a self-reported demographic and psychological assessment, a clinician-administered craving and emotional reaction test, and will also be monitored using a smartwatch. SUD participants will be monitored for a total of 18 months (6 months during rehabilitation, an additional 12 months post discharge), and control participants for a total of 6 months. All participants will be reassessed at the sixth month of monitoring. The collected data will then be used to train models with a neural network, which will then be validated against other models and compared with other algorithms. Demographic, psychological, digital biomarkers, and craving profiles will be created, correlations will be analyzed, and they will be compared with controls to generate a digital phenotype of SUD. When the model achieves adequate validity (area under the curve of ≥0.80), a graphic user interface will then be designed for clinical use. Results: The study is supported by the Program for the Improvement of Working Conditions for Members of the SNII and SNCA (PROSNII U006EST), and APPAC-VII-CUCS-2025 for Article Publication Fees, from the University of Guadalajara. The research protocol was approved by the University of Guadalajara (reference CI-01225) in January 2025. Recruitment of patients with SUD and control participants will take place from January 2025 through January 2027. Conclusions: As shown in recent studies, accessible and affordable wearables, like commercial smartwatches, combined with psychological, demographic, and emotional state data, used with a machine learning predictive model, may be able to be used as tools to enhance SUD rehabilitation and prevent relapse. International Registered Report Identifier (IRRID): PRR1-10.2196/71374

31 October 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
AGAndrea P. Garzón-Partida
Andrea P. Garzón-Partida
IGIrene Guadalupe Aguilar Garcia
Irene Guadalupe Aguilar Garcia
JGJoaquin Garcia-Estrada
Joaquin Garcia-Estrada
SLSonia Luquin
Sonia Luquin
Substance use disorder (SUD) significantly impacts public health, economics, and legal systems worldwide. Eye Movement Desensitization and Reprocessing (EMDR) was initially developed in the late 1980s as a therapeutic approach for post-traumatic stress disorder (PTSD), using bilateral stimulation to integrate traumatic memories with calming physiological responses. However, the effectiveness of EMDR in treating SUD remains unclear. This study aims to conduct a systematic review and meta-analysis of the impact of EMDR therapy on craving reduction in individuals with SUD. The search was conducted using databases such as PubMed and Web of Science, focusing on studies that measured craving and employed EMDR interventions. Both random and fixed effects models were used to pool effect sizes, utilizing an R software meta-package (R-4.4.1). The study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The results indicated a significant reduction in cravings among patients undergoing EMDR therapy. Specifically, under the fixed effect model, the standardized mean difference (SMD) was −0.866 with a 95% confidence interval ranging from −1.121 to −0.611 (z = −6.66, p < 0.0001). These findings may demonstrate the significant efficacy of EMDR therapy in decreasing cravings in people with SUD.

16 January 2025 in JMIR Preprints
Verified
Preprint
Open access
AGAndrea P. Garzón-Partida
Andrea P. Garzón-Partida
KMKimberly Magaña-Plascencia
Kimberly Magaña-Plascencia
DMDiana Emilia Martínez-Fernández
Diana Emilia Martínez-Fernández
JGJoaquin Garcia-Estrada
Joaquin Garcia-Estrada
SLSonia Luquin
Sonia Luquin
David Fernández-QuezadaDavid Fernández-Quezada
David Fernández-Quezada
BACKGROUND Substance use disorder (SUD) involves excessive substance consumption and persistent reward-seeking behaviors, leading to serious physical, cognitive, and social consequences. This disorder is a global health crisis tied to increased mortality, unemployment, and reduced quality of life. Altered brain connectivity, circadian rhythms, and dopaminergic pathways contribute to sleep disorders, anxiety, and stress, which worsen SUD severity and relapse. Factors like trauma and socioeconomic disadvantages heighten risk. Digital health technologies, including wearables and machine learning, show promise for diagnosis, monitoring, and intervention, from relapse prediction to early detection of comorbidities. With high relapse rates and younger patient cases, these innovations could enhance the treatment outcomes of SUD. OBJECTIVE The objective of this study is to develop and validate a predictive model with machine learning for the duration of therapy and the rehabilitation or relapse in patients with SUD, using digital physiological measurements, psychological profiles, automatic facial emotion recognition, and the emotional state during craving. METHODS The study will be conducted with adult male patients with SUD at a rehabilitation center and control volunteers. Participants will undergo a self-reported demographic and psychological assessment, a clinician-administered craving and emotional reaction test, and will also be monitored using a smartwatch. SUD participants will be monitored for a total of 18 months (6 months during rehabilitation, an additional 12 months post discharge), and control participants for a total of 6 months. All participants will be reassessed at the sixth month of monitoring. The collected data will then be used to train models with a neural network, which will then be validated against other models and compared with other algorithms. Demographic, psychological, digital biomarkers, and craving profiles will be created, correlations will be analyzed, and they will be compared with controls to generate a digital phenotype of SUD. When the model achieves adequate validity (area under the curve of ≥0.80), a graphic user interface will then be designed for clinical use. RESULTS The study is supported by the Program for the Improvement of Working Conditions for Members of the SNII and SNCA (PROSNII U006EST), and APPAC-VII-CUCS-2025 for Article Publication Fees, from the University of Guadalajara. The research protocol was approved by the University of Guadalajara (reference CI-01225) in January 2025. Recruitment of patients with SUD and control participants will take place from January 2025 through January 2027. CONCLUSIONS As shown in recent studies, accessible and affordable wearables, like commercial smartwatches, combined with psychological, demographic, and emotional state data, used with a machine learning predictive model, may be able to be used as tools to enhance SUD rehabilitation and prevent relapse. CLINICALTRIAL INTERNATIONAL REGISTERED REPORT PRR1-10.2196/71374